Could Contentious IPR Trade Terms Bloat Healthcare Costs, Sink Pharma’s Image?
Intellectual property rights terms in various trade agreements could have serious ramifications not just on healthcare costs but also on the legitimate trade of generic drugs between developing nations, say some experts. Pharma’s image may be at stake too.
You may also be interested in...
President Trump has indicated the US may be interested in rejoining the Trans-Pacific Partnership free trade talks, but there would be multiple obstacles, not least whether strict US conditions could be met, including in the pharma IPR area. PhRMA meanwhile voices concerns over recent Japanese reforms.
Humanitarian group MSF says India is facing “pincer-like pressure” to relax its strict patent laws in order to conclude free trade deals in Europe and Asia, and is calling on New Delhi to stand firm.
A bill implementing the provisions of the EU-Canada CETA trade deal is expected to be approved soon, bringing a new Certificate of Supplementary Protection together with an export manufacturing waiver, and some changes to the patent litigation system.